Gliptins – do they increase cardiovascular risk or benefit?

Author： Doggrell Sheila A   Dimmitt Simon B  

Publisher： Informa Healthcare

ISSN： 1474-0338

Source： Expert Opinion on Drug Safety, Vol.13, Iss.5, 2014-05, pp. : 675-680

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Related content

Cardiovascular Risk-Benefit Profile of Sibutramine

By Scheen A.J.  

American Journal of Cardiovascular Drugs, Vol. 10, Iss. 5, 2010-10 ,pp. : 321-334

Adis International

Access to resources Recommend Favorite

-adrenoceptor agonists increase cardiovascular risk

By  

Inpharma, Vol. 1, Iss. 1451, 2004-01 ,pp. : 16-16

Adis International

Access to resources Recommend Favorite

Do Inhaled Anticholinergics Increase or Decrease the Risk of Major Cardiovascular Events?: A Synthesis of the Available Evidence

By Salpeter Shelley R.  

Drugs, Vol. 69, Iss. 15, 2009-10 ,pp. : 2025-2033

Adis International

Access to resources Recommend Favorite

Triptans: no increase in stroke or cardiovascular event risk

By  

Inpharma, Vol. 1, Iss. 1429, 2004-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Why Does Obesity Increase the Risk for Cardiovascular Disease?

By  

Current Pharmaceutical Design, Vol. 19, Iss. 32, 2013-10 ,pp. : 5678-5683

Bentham Science Publishers

Access to resources Recommend Favorite